DD01

DRUG2 trials

Sponsors

Neuraly, Inc.

Conditions

NAFLDNASHOverweight and ObesityType2 Diabetes

Phase 1

A Phase 1 Study of DD01 in Overweight/Obese Subjects With T2DM and NAFLD

CompletedNCT04812262

Neuraly, Inc.NAFLD, Overweight and Obesity, Type2 Diabetes

Start: 2021-02-24End: 2023-02-14Updated: 2024-04-29

Phase 2

A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH

CompletedNCT06410924

Neuraly, Inc.NAFLD, NASH

Start: 2024-06-13End: 2026-04-21Updated: 2026-05-01

Related Papers

The glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, double-blind, multicentre, placebo-controlled, phase 2 trial.

2026-07-21